06 December 2023
06 December 2023
Discussions at the 10th CTO Europe conference reflected old and new challenges that add pressure on companies running oncology trials.
Evobrutinib’s safety and tolerability profile in the trials was found to be in line with those seen in the Phase II trial.
The safety and tolerability profile of PrimeC in the PRADIGM trial was similar to the placebo.
Post-hoc analysis of two Phase III studies demonstrated that the safety and efficacy of Ajovy were the same in patients with obesity compared to normal-BMI patients.
The Phase IIa trial will be the first time the candidate is investigated in patients with major depressive disorder (MDD).
The YouGov poll found that the majority of the UK’s public thinks clinical trials need to include a diverse population, regardless of timelines and costs.
The Phase Ib trial will evaluate the combination therapy of Welireg and HC-7366 in patients with clear cell renal cell carcinoma.
The trial will enrol 480 participants with moderate to severe acne vulgaris in China.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
